Pathogenesis of Nigral Cell Death in Parkinson’s Disease
During the past several years, several important findings which may play a role in the degeneration of nigral cell in Parkinson’s disease (PD) have been disclosed (Table 1). In this review, we will critically discuss the significance and implications of those findings including the question as to whether those findings are the primary defects or the secondary effects of an as yet undiscovered primary abnormality in PD. In Parkinson’s disease, we cannot dismiss secondary abnormalities as they may interfere with the regenerative and restorative processes, and may contribute to the progression of the disease. We would like to start our discussion with iron accumulation in Parkinson’s disease.
KeywordsTyrosine Hydroxylase Substantia Nigra Monoamine Oxidase Iron Accumulation Parkinson Disease Patient
Unable to display preview. Download preview PDF.
- Ikebe, S., Hattori, N., Mizuno, Y., Tanaka, M., and Ozawa, T., 1992, Point mutations of mitochondrial DNA in Parkinson’s disease, Abst. Mov. Disord. 7, Supp1. 1: 71.Google Scholar
- Linnane, A.W., Marzuki, S., Ozawa, T., and Tanaka, M.,1989, Mitochondria) DNA mutations as an important contributor to ageing and degenerative diseases, Lancet 1: 642–645.Google Scholar
- Mizuno, Y., Matuda, S., Yoshino, H., Mori, H., Hattori, N., and Ikebe, S., 1993, An immuno-histochemic al study on a-ketoglutarate dehydrogenase complex in Parkinson’s disease. Ann. Neurol., in press.Google Scholar
- Mochizuki, H., Nishi, K., and Mizuno, Y., 1993, Iron-melanin complex is toxic to dopaminergic neurons in a nigrostriatal co-culture, Neurodegeneration 2: 1–7.Google Scholar
- Moll, G., Moll, R, Riederer, P., Gsell, W., Heinsen, H., and Denney, R.M., 1990, Immunofluorescence cytochemistry on thin frozen sections of human substantia nigra for staining of monoamine oxidase A and monoamine oxidase B: a pilot study, J. Neural. Transm. Suppl. 32: 67–77.Google Scholar
- Nagatsu, T., and Yoshida, M.,1988, An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterine in the nigrostriatal regions, Neurosci. Lett. 87: 178–182.Google Scholar
- Naoi, M., Takahashi, T., Parvez, H., Kabeya, R., Taguchi, E., Yamaguchi, K., Hirata, Y., Minami, M., and Nagatsu, Y., 1989, N-methylisoquinolinium ion as an inhibitor of tyrosine hydroxylase, aromatic Lamino acid decarboxylase and monoamine oxidase, Neurochem. Int. 15: 315–320.PubMedCrossRefGoogle Scholar
- Philbert, M.A., Beiswanger, C.M., Waters, D.K., Reuhl, K.R., and Lowndes, H.E., 1991, Cellular and regional distributions of reduced glutathione in the nervous system of the rat: histochemical localization by mercury orange and o-phthalaldehyde-induced histofluorescence, Toxicol. App. Pharmacol. 107: 215–227.CrossRefGoogle Scholar
- Schapira, A.H.V., Holt, U., Sweeney, M., Harding, A.E., Jenner, P., and Marsden, C.D.,1990, Mitochondrial DNA analysis in Parkinson’s disease, Mov. Disord. 5: 294–297.Google Scholar
- Shoffner, J.M., Brown, M.D., Torroni, A., Lott, M.T., Cabell, M.F., Mirra, S.S., Beal, M.F., Yang, C.C., Gearing, M., Salvo, R., Watts, R.L., Juncos, J.L., Hansen L.A., Crain, B.J., Fayad, M., Reckord, C.L., and Wallace, D.C., 1993, Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients, Genomics 17: 171–184.PubMedCrossRefGoogle Scholar
- Smith, C.A., Gough, A.C., Leigh, P.N., Summers, B.A., Harding, A.E., Maranganore, D.M., Sturman, S.G., Schapira, A.V., Williams, A.C., Spun, N.K., and Wolf, C.R., 1992, Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease, Lancet 339: 1375–1377.PubMedCrossRefGoogle Scholar